AJMC - The American Journal of Managed Care’s Post

PCC's new 2024 Evidence Report found that primary care centric ACOs in MSSP outperform their peers, generating 2.4x times the savings. In a recent Medical Economics piece, Austin Littrell provides a breakdown here: https://lnkd.in/dSDEheSU

“No business or professional sports team would allow a continuation of such a poor win loss record The ACO promotions are not helpful 1. Benchmark comparisons are deceptive 2. The funding saved is a tiny fraction 3. The costs of the intervention are not all covered 4. The burdens on delivery team members are not all included 5. Gaming helps profits and is not helping patients 6. Arbitrary measures are not the same as quality This ACO promotion is no home run and is not even a single and it could be an out with all things considered.”

This latest #PwC study notes that "...GLP-1s in particular as a driver to watch. Costs per member on GLP-1s have risen steadily over the past several years, reaching $23.16 in the first half of 2023 compared to $8.99 in 2021." No surprise there and expect both demand and costs to continue. #Obesity is one of the significant drivers of GLP-1 demand. Click on this on-demand #IQVIAInstitute webinar to learn more: Rethinking Obesity: Impact on Healthcare Economics and Clinical Practice (on24.com)

Recent publication: Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study. Message from the authors: Pill burden leads to a significant impact on health related quality of life. Let us try to minimize the anticholinergic burden. Recognition: Eyob Alemayehu Gebreyohannes Segenet Bizuneh University of Gondar Article link: https://lnkd.in/ebh76g-v

I applaud Stacy Hurt 🌻 for writing a thoughtful piece regarding compensation of Clinical Trial participants. Financial concerns should not a critical factor in a Patient’s decision train for healthcare, regardless of the disease or health need. A Clinical Research trial, as mentioned in the article, is often a second (or sometimes third thought) after an initial one or two lines of therapy has been exhausted. There are ways in which Sponsors can be discussing how to compensate patients, especially in these more challenging facial times nationally. And looking more in depth too into their desires for increasing diversity amongst their oatient populations, the need to take a more thorough analysis of the needs of every Patient is quite great. I highly recommend reading this shared piece. Extremely thought provoking. #patientsfirst

Yet another study highlights the undeniable benefits of care coordination. This study expands on previous research by examining not just TCM, but also unbilled care transitions. The real breakthrough will come with an analysis that pinpoints the optimal combination, timing, and personalization of coordination activities to drive specific improvements in quality, cost, and utilization. Advances in probabilistic modeling, study design, and more granular outcomes tracking will be essential to unlocking these insights—and they can’t arrive soon enough.

According to American Journal of Medicine, more than 42 percent of the 9.5 million people diagnosed with cancer from 2000 to 2012 drained their life's assets within two years. From my own lived patient/advocacy experience, I can tell you this included people (1) undergoing standard of care (SOC) treatment, and (2) with insurance. As the current model exists (realistically speaking), patients explore #clinicaltrials after SOC, which means that they are already experiencing a high level of financial toxicity, not to mention emotional, physical, and mental stress from their illness. There are already so many barriers to participating in clinical research. Why should financial considerations be among them when these factors are well within our control with some focused, collaborative actions? Please read my thoughts in STAT, and of course, I consulted with patients 😃: https://lnkd.in/e9FTYesy and comment below 👇 with your innovative ideas to help bridge this gap for the sake of #healthequity 🤝 James Edwards Rasu Shrestha MD MBA Lygeia Ricciardi Dr. Geeta Nayyar, MD, MBA Jane Sarasohn-Kahn Evan Kirstel B2B TechFluencer Gil Bashe Ritesh Patel Craig Lipset Samuel Whitaker Irma Rastegayeva✨Influence Through Storytelling™️ Ceci Connolly Helen Burstin Grace Vinton Matt Toresco Matthew Zachary Christine Von Raesfeld 💜 T.J. Sharpe Grace Cordovano, PhD, BCPA Jen Horonjeff - “Ask Patients” MaryAnne Rizk, Ph.D. Deirdre BeVard Alberto Grignolo Ph.D., FDIA Carlos E. Orantes Kimberly Richardson Richie Kahn Seth Rotberg, MNM Joe DustinAlicia C. Staley

Holding administrators accountable for health outcomes is on the horizon.

👨⚕️👩⚕️Healthcare professionals in the U.S. are largely supportive of psychedelic-assisted therapies (PAT) using substances like psilocybin and MDMA, but their knowledge about these treatments is limited. 📝 A study published in Scientific Reports, led by researchers from Johns Hopkins University, surveyed 879 healthcare providers to assess their attitudes, knowledge, and concerns about PAT. . The study revealed a significant gap between healthcare workers' self-reported knowledge and their actual understanding of psychedelics in clinical settings. While 93% of respondents endorsed psilocybin's potential and 76% supported MDMA's promise, only 5.5% and 1.1% respectively answered all knowledge questions correctly about these substances. . The main worries (rightly so!) among healthcare professionals included: ▶️ Lack of trained providers (59% expressed concern) ▶️ Financial cost of treatment ▶️ Potential risks for patients with contraindications . The study highlights the need for comprehensive clinical training and evidence-based education on psychedelics in healthcare. As interest in PAT grows, addressing these knowledge gaps and expanding formal training will be crucial for the safe and effective integration of these therapies into mainstream healthcare1 . #mdma #psychedelictherapy #healthcareeducation #mentalhealth Article 🔗 in the comments.